Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Celgene Corporation    CELG

Delayed Quote. Delayed  - 09/27 10:00:00 pm
107.4 USD   +1.03%
09/26 CELGENE CORPORA : - A Challenging yet Rewarding Journey Towards a My..
09/21 CELGENE : Glenmark announces Strategic Development and Global Licens..
09/21 AGIOS PHARMACEU : Appoints Andrew Hirsch as Chief Financial Officer
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Celgene Corporation : Celgene 1st-Quarter Net Down 4.1% Amid Increased Costs

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/25/2013 | 02:25pm CEST
   By Ben Fox Rubin 
 

Celgene Corp.'s (CELG) first-quarter profit fell 4.1% as the drug maker saw higher expenses offset stronger revenue from its Revlimid and Vidaza drugs.

The company raised its full-year guidance to a range of $5.55 to $5.65 a share in adjusted earnings from $5.50 to $5.60. It also backed its full-year product sales outlook.

Celgene has continued to post improved revenue, with its flagship blood-cancer treatment Revlimid grabbing more market share and sales of Vidaza, a blood-cancer treatment that lost patent exclusivity in May 2011, continuing to rise in the face of generic competition. The biopharmaceutical company also is expanding its core hematology franchise and building out new product lines in cancer and psoriasis as part of a strategy to achieve $12 billion in product sales by 2017.

Celgene reported a profit of $384.9 million, or 89 cents a share, down from $401.5 million, or 90 cents, a year earlier. Excluding items such as stock-based compensation, per-share earnings rose to $1.37 from $1.08.

Revenue grew 15% to $1.46 billion.

Analysts polled by Thomson Reuters had most recently forecast earnings of $1.35 a share on revenue of $1.47 billion.

Total costs and expenses rose 27%.

Revlimid sales were up 16% to $1 billion while Vidaza sales rose 10% to $204 million.

Shares closed Wednesday at $118.28 and were down 0.2% premarket. The stock has gained 51% so far this year.

Write to Ben Fox Rubin at ben.rubin@dowjones.com

Order free Annual Report for Celgene Corp.

Visit http://djnweurope.ar.wilink.com/?ticker=US1510201049 or call +44 (0)208 391 6028

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on CELGENE CORPORATION
09/26 CELGENE CORPORATION : - A Challenging yet Rewarding Journey Towards a Myeloma Cu..
09/21 CELGENE : Glenmark announces Strategic Development and Global Licensing Agreemen..
09/21 AGIOS PHARMACEUTICALS : Appoints Andrew Hirsch as Chief Financial Officer
09/20 GLENMARK PHARMACEUTICALS : Particle to develop cancer drug
09/16 CELGENE : Oral Ozanimod Efficacy and Safety Results at 2 Years from Phase 2 RADI..
09/15 CELGENE : Announces Interim Topline Data from Trial of Investigational Oral GED-..
09/13 CELGENE : First-Ever Psoriatic Arthritis Awareness Day Aims to Educate on Import..
09/12 CELGENE CORP /DE/ : Other Events (form 8-K)
09/12 CELGENE : Announces Interim Topline Data from Trial of Investigational Oral GED-..
09/12 CELGENE : Announces Interim Topline Data from Trial of Investigational Oral GED-..
More news
Sector news : Bio Therapeutic Drugs
02:18pDJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJPfizer Throws Out Plan to Split Into Two Companies
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
11:11a Allergan Validates Gilead Sciences NASH Pipeline
09/26 Game Plan For The Week - Cramer's Mad Money (9/23/16)
09/22 Reviewing Fortune's 20 'Best Investments' Of The Last Decade
09/22 Biotech ETF IBB Could Get A Boost From A Potential Gilead Merger Or Acquisiti..
09/20 Deal Flurry Shines Spotlight On Novel Multiple Myeloma Target
Advertisement
Financials ($)
Sales 2016 11 080 M
EBIT 2016 5 788 M
Net income 2016 3 415 M
Debt 2016 7 253 M
Yield 2016 -
P/E ratio 2016 26,49
P/E ratio 2017 18,77
EV / Sales 2016 8,09x
EV / Sales 2017 6,66x
Capitalization 82 402 M
More Financials
Chart CELGENE CORPORATION
Duration : Period :
Celgene Corporation Technical Analysis Chart | CELG | US1510201049 | 4-Traders
Full-screen chart
Technical analysis trends CELGENE CORPORATION
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 138 $
Spread / Average Target 30%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Alles Chief Executive Officer & Director
Jacqualyn A. Fouse President, Chief Operating Officer & Director
Robert J. Hugin Executive Chairman
Peter N. Kellogg Chief Financial Officer & Executive Vice President
Joseph S. Camardo Senior Vice President-Global Medical Affairs
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
CELGENE CORPORATION-11.23%82 402
AMGEN, INC.6.90%129 863
GILEAD SCIENCES, INC.-20.33%106 391
REGENERON PHARMACEUTIC..-25.56%42 552
VERTEX PHARMACEUTICALS..-29.83%21 876
ACTELION LTD21.56%18 591
More Results